Analysis of relations between serum levels of epitestosterone, estradiol, testosterone, IGF-1 and prostatic specific antigen in men with benign prostatic hyperplasia and carcinoma of the prostate

Physiological Research

Volumn 49, Issue SUPPL. 1, 2000, Pages

  Hill, M ^a,b   Bilek R ^a   Safarik L ^a   Starka L ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Carcinoma; Epitestosterone; Estradiol; Insulin like growth factor; Prostate; Prostatic specific antigen

Indexed keywords

ANDROGEN RECEPTOR; EPITESTOSTERONE; ESTRADIOL; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; STEROIDOGENESIS; TUMOR CELL LINE;

AGE FACTORS; AGED; EPITESTOSTERONE; ESTRADIOL; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STATISTICS; TESTOSTERONE;

EID: 0034046052     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. 2+ influx in LNCaP human prostate cancer cells. Eur J Endocrinol 135: 367-373, 1996.
2. BIČÍKOVÁ M, HAMPL R, STÁRKA L: Epitestosterone - a potent competitive inhibitor of C21-steroid side chain cleavage in the testis. J Steroid Biochem Mol Biol 43: 721-724, 1992.
3. BIČÍKOVÁ M, HILL M, HAMPL R, STARKA L: Inhibition of rat renal and testicular 11 beta-hydroxysteroid dehydrogenase by some antihypertensive drugs, diuretics, and epitestosterone. Horm Metab Res 29: 465-468, 1997.
4. BÍLEK R, HAMPL R, PUTZ Z, STÁRKA L: Radioimmunoassay of epitestosterone: methodology, thermodynamic aspects and applications. J. Steroid Biochem 28: 723-729, 1987.
5. CHAN JM, STAMPFER MJ, GIOVANUCCI E, GANN PH, MA, J. WILKINSON P, HENNEKENS CH, POLLAK M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
6. CULIG Z, HOBISCH A, CRONAUER MV, RADMAYR C, TRAPMAN J, HITTMAYR A, BARTSCH G, KLOCKER H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
7. CULIG Z, HOBISCH A, CRONAUER M.V, HITTMAYR A, RADMAYR C, BARTSCH G, KLOCKER H: Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J Urol 13: 285-289, 1995.
8. CUTTING CW, HUNT C, NISBET JA, BLAND JM, DALGLEISH AG, KIRBY RS: Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 83: 996-999, 1999.
9. FARNSWORTH WE: Roles of estrogen and SHBG in prostate physiology. Prostate 28: 17-23, 1996.
10. KANETY H, MADJAR Y, DAGAN Y, LEVI J, PAPA MZ, PARIENTE C, GOLDWASSER B, KARASIK A: Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77: 229-233, 1993.
11. MAUCHER A, VON ANGERER E, HAMPL R, STARKA L: The activity of epitestosterone in hormone dependent prostate tumour models. Endocr Regul 28: 23-29, 1994.
12. MONSALVE A, BLAQUIER JA: Partial characterization of epididymal 5 alpha reductase in the rat. Steroids 30: 41-51, 1977.
13. NUCK BA, LUCKY AW: Epitestosterone: a potential new antiandrogen. J Invest Dermatol 89: 209-211, 1987.
14. PERUSQUIA M, HERNÁNDEZ R, KUBLI-GARFIAS C: Epitestosterone induces testosterone-like uterine relaxation. Abstr 10th Congr Endocrinol, San Francisco, 1996, vol. 1, p 549, abstract No 2-578.
15. STARKA L, HAMPL R, BIČÍKOVÁ M, JELÍNEK R, DOSKOČIL M: Observations on the biological activity of epitestosterone. Physiol Res 40: 317-326, 1991.